UTTAR PRADESH, India — Jubilant Life Sciences, an integrated pharmaceuticals and life sciences company, last week announced that it received approval from the Food and Drug Administration for spironolactone tablets, 25 mg, 50 mg and 100 mg, which is the generic version of Aldactone. The drug is used to treat fluid retention caused by congestive heart failure and cirrhosis of the liver.
The market size for spironolactone tablets is $87 million per annum, according to IMS data. The company said it expects to launch the product in first quarter 2015.
The company also received FDA approval for memantine tablets, 5 mg and 10 mg, the generic form of Namenda from Forest Labs. Memantine tablets are used for the treatment of moderate-to-severe Alzheimer’s disease. The drug is expected to launch after the patent expiry in 2015, the company said.